Lateral one-third gland resection in Cushing patients with failed adenoma identification leads to low remission rates: long-term observations from a small, single-center cohort

Lukas Andereggen¹ ² • Luigi Mariani³ • Jürgen Beck⁴ • Robert H. Andres¹ • Jan Gralla⁵ • Markus M. Luedi⁶ • Joachim Weis⁷ • Emanuel Christ⁸

Received: 26 January 2021 / Accepted: 23 March 2021 / Published online: 3 April 2021
© The Author(s) 2021

Abstract

Background Currently, there are no guidelines for neurosurgeons treating patients with Cushing’s disease (CD) when intraoperative adenoma identification is negative. Under these circumstances, a total hypophysectomy or hemi-hypophysectomy on the side indicated by inferior petrosal sinus sampling (IPSS) is the approach being used, although there is a subsequent risk of hypopituitarism. Data on whether one-third lateral pituitary gland resection results in cure of hypercortisolism and low rates of hypopituitarism remain inconclusive.

Methods Retrospective single-center study of CD patients with failed intraoperative adenoma identification and subsequent resection of the lateral one-third of the pituitary gland as predicted by IPSS. We assessed (i) histopathological findings, (ii) early and long-term remission rates, and (iii) rates of additional pituitary hormone insufficiency.

Results Ten women and three men met the inclusion criteria. At 3 months, remission was noted in six (46%) patients: three (23%) had histologically confirmed adenomas, two (15%) had ACTH hyperplasia, and one patient (8%) was positive for Crooke’s hyaline degeneration. New pituitary hormone deficits were noted in two patients (15%). After a median (±SD) follow-up of 14±4 years, recurrence was noted in two (15%) patients. Long-term control of hypercortisolism was attained by 10 patients (77%), with additional therapies required in nine (69%) of them.

Conclusions In CD patients with failed intraoperative adenoma visualization, lateral one-third gland resection resulted in low morbidity and long-term remission in 31% of patients without the need for additional therapies. Bearing in mind the sample size of this audit, the indication for lateral one-third-gland resection has to be critically appraised and discussed with the patients before surgery.

Keywords Cushing’s disease • Remission • Adenoma • Petrosal sinus sampling, Pituitary surgery
Introduction

Cushing’s disease (CD) is the most challenging disorder among hormone-secreting pituitary tumors [13]. CD is predominantly caused by a corticotroph pituitary microadenoma [62]. Despite modified protocols, not infrequently magnetic resonance imaging (MRI) fails to detect adrenocorticotropin-secreting (ACTH) pituitary microadenomas [20, 22, 65]. Thus, bilateral inferior petrosal sinus sampling (IPSS) remains the gold standard in identifying the source of Cushing’s syndrome (CS) in patients with negative or equivocal MRI findings [7, 10]. Nevertheless, subsequent intraoperative exploration still might reveal a pituitary gland with a normal appearance [7, 10]. Under these circumstances, no commonly accepted treatment guidelines exist, and hemi-hypophysectomy—or two-thirds gland resection—has been proposed as a valid option, with a subsequent risk of hypopituitarism [19]. Data remain inconclusive with regard to whether one-third resection of the pituitary gland on the side indicated by IPSS results in high remission rates and a low rate of additional pituitary hormone deficiencies.

In this audit of practice, we assessed (i) histopathological findings, (ii) early and long-term remission rates, and (iii) the rate of new pituitary hormone insufficiency in CD patients with negative MRI findings, failed intraoperative adenoma exploration, and subsequent lateral one-third gland resection on the side indicated by IPSS. Emphasis was placed on assessing the long-term outcome in these patients, given that high long-term recurrence rates are known [11, 49].

Methods

Study design

We performed a retrospective study evaluating data from our institutional database, which was prospectively maintained from October 1997 to January 2016. All consecutive patients met clinical and biochemical inclusion criteria for ACTH-dependent CS [27, 34, 64]. Bilateral IPSS was performed due to failed adenoma identification by pituitary MRI. Patients were included if the adenomas could not be identified intraoperatively after careful exploration of the entire gland at the time of transsphenoidal surgery (TSS). Thus, the lateral one-third of the pituitary gland was subsequently resected on the side indicated by IPSS. Tissue was sent to pathology for histological analysis. Early remission rates, hypopituitarism, and long-term outcome were extracted from the medical records.

MR imaging and bilateral IPSS

PD/T2-weighted, unenhanced, contrast-enhanced, dynamic contrast-enhanced, and post contrast-enhanced overlapping images in three planes over the pituitary region of 1-mm fine-cut images were collected using a 1.5 Tesla MRI [6, 9, 10]. In patients with negative MRI and ACTH-dependent CS with equivocal responses to biochemical testing (i.e., ovine corticotropin-releasing hormone [oCRH] stimulation and/or high-dose dexamethasone suppression), bilateral IPSS was indicated [7, 10]. Details of this procedure have been described previously [7, 10]. In brief, both femoral veins were catheterized. A Hi-Flow Tracker 18 (Renegade Hi-Flow Microcatheter; Boston Scientific Target, Fremont, CA) was placed into each cavernous sinus to enable classification of the venous outflow on both sides. If the cavernous sinus could not be catheterized, the drainage type was recorded based upon an internal carotid artery injection. For venous blood sampling, the microcatheter was retracted distal to the cavernous sinus and placed into each proximal IPS. We determined the venous outflow variances on each side of the IPS after contrast injection and classified them as described by Shiu et al. [61] and Benndorf et al. [12]. An asymmetric IPS was defined as different venous outflow patterns of IPS seen when comparing the left and right sides.

As proposed by Oldfield et al., mean ACTH concentration of both the petrosal sinuses, divided by mean ACTH concentration of a peripheral vein, was indicative of a central ACTH source when gradients were ≥2.0 before and/or ≥3.0 after oCRH stimulation [47]. As for lateralization, mean ACTH concentration of one side of the petrosal sinuses divided by mean ACTH concentration of the other side was positive if gradients were ≥1.4 [46].

Microsurgery

A transnasal transsphenoidal approach under microscopic magnification was used in all cases [28]. All operations were performed by the senior neurosurgeon (RWS).

As microadenomas can induce limited bulging in the surface of the gland, we created a wide opening in the sellar floor to thoroughly expose the pituitary gland after extensive dural opening. The superior and inferior surfaces of the gland, as well as the lateral walls in direct contact with the medial wall of the cavernous sinus, were explored, and the lateral ligaments were divided, allowing for easier mobilization and inspection of the pituitary gland’s lateral surface [30]. If no bulging was noticeable, a vertical incision was made in the lateral gland on the side where the adenoma was suspected to be found, in order to explore the inside of the gland. Suspicious tissue was sent for frozen sectioning. If no adenoma was confirmed, a lateral one-third hypophysectomy was performed using pituitary rongeurs on the side indicated by IPSS (Fig. 1). This included the bottom of the gland in order to maximize the chance of microadenoma removal while minimizing new endocrinopathies [24, 30, 31, 60].
Histopathological analyses

Histopathological analyses were performed to confirm the presence of an ACTH-secreting adenoma. In brief, paraffin sections were stained for hematoxylin, reticulin, and ACTH. In addition, staining was performed for growth hormone, prolactin, thyroid-stimulating hormone, luteinizing hormone, and follicle-stimulating hormone. If no adenoma was found, the tissue was examined for ACTH hyperplasia or positive Crooke’s hyalinization as an indirect marker of hypercortisolism [48].

Determination of remission rates

The early remission rate was determined 3 months postoperatively. Long-term remission rates were extracted ≥ 12 months postoperatively. Remission was defined as immediate postoperative serum cortisol <50 nmol/L and the need for a transitory cortisol replacement therapy. In addition to improvement in the clinical features of CS, remission was defined as normalization of 24 h urinary cortisol levels, normal salivary cortisol levels for three consecutive days, and/or a normal dexamethasone suppression test during the follow-up visit [27, 41, 64].

Statistical analyses

Data were analyzed using IBM SPSS statistical software Version 24.0 (IBM Corp., New York, NY, USA) and GraphPad Prism (V7.04 Software, San Diego, CA, USA). Continuous variables were examined for homogeneity of variance and are expressed as mean ± standard deviation (SD) unless otherwise noted. For comparisons of means between the two groups, Student’s t-test was used for normally distributed data, and the Mann-Whitney test for non-parametric data. Categorical variables were compared using Pearson’s chi-square test or Fisher’s exact test, as appropriate. Differences were considered significant at p < 0.05 for reported two-sided p values.

Results

Patients’ characteristics

Ten women (77%) and three men (23%) met the study inclusion criteria. Patients’ characteristics are summarized in Table 1. Median age was 49 ± 12.4 years (range 24–63 years). All patients had negative MRI results and underwent IPSS, with the latter predicting a pituitary (central) lesion. Preoperative pituitary deficits were rare. Two patients (15%) showed isolated one-axis impairment (gonadotrophic deficiency in one patient and thyrotropic deficiency in another patient).

Bilateral IPSS results

In Supplementary Table 1, classification of the venous outflow and documentation of the venous outflow symmetry are summarized. In addition, central to peripheral ACTH gradients and intersinus gradients (lateralization data) before and after oCRH stimulation are depicted.

In three patients, no data on the drainage pattern were available. Symmetric outflow was recorded in eight patients (62%) and asymmetric outflow in two patients (15%). A central-to-peripheral gradient ≥2.0 before oCRH stimulation was attained in 10 patients (77%), whereas a gradient ≥3.0 after oCRH stimulation was attained in all of them (100%). With regard to lateralization, normalized ACTH values (i.e., side-by-side gradients) were not significantly different between patients with a symmetric (7.3 ± 2.6) or an asymmetric outflow at baseline (18.2 ± 13.4; p = 0.19), but they were significantly different after oCRH stimulation (symmetric: 9.0 ± 4.9 versus asymmetric: 141.0 ± 93.9; p = 0.01).

We further noted that ACTH gradients were higher in patients with a histologically confirmed adenoma compared to those without, both before (19.2±8.7 vs. 6.6 ± 2.6; p=0.12) and after (74.8± 43 vs. 9.6 ± 5.5, p=0.08) oCRH stimulation.
but not significantly. In addition, early remission rates were found not to be significantly different in patients with higher ACTH gradients compared to those with lower gradients, both before (12.2 ± 5 vs. 10.8 ± 6.2, \(p = 0.87\)) and after (43.1 ± 38 vs. 27.4 ± 12.6; \(p = 0.69\)) oCRH stimulation.

**Histopathological results**

An ACTH-secreting adenoma was histologically confirmed in five patients (39%), an ACTH hyperplasia in four (31%), positive Crooke-hyaline in three patients (23%), and a normal pituitary gland in one patient (7%).

| Case No. | Age (yrs), sex | IPSS prediction | Histopathology | Early remission at 3 months | Long-term remission (months) | Additional therapy |
|----------|----------------|----------------|----------------|-----------------------------|-----------------------------|-------------------|
| 1        | 53, m          | Central left   | Normal pituitary | No                          | Yes (203)                   | Bilateral adrenalectomy |
| 2        | 41, f          | Central right  | ACTH hyperplasia | Yes                         | Yes (156)                   | None              |
| 3        | 49, f          | Central left   | Adenoma         | No                          | Yes (180)                   | Bilateral adrenalectomy |
| 4        | 40, f          | Central right  | Adenoma         | Yes                         | Yes (228)                   | None              |
| 5        | 52, f          | Central left   | Adenoma         | Yes                         | No (128)                    | Drug-treated       |
| 6        | 37, f          | Central right  | ACTH hyperplasia | Yes                         | No (168)                    | Gamma-knife surgery |
| 7        | 50, f          | Central left   | Adenoma         | Yes                         | Yes (171)                   | None              |
| 8        | 63, f          | Central left   | ACTH hyperplasia | No                          | Yes (170)                   | Drug-treated       |
| 9        | 55, m          | Central right  | ACTH hyperplasia | No                          | Yes (64)                    | None              |
| 10       | 60, f          | Central right  | pos. Crooke hyaline | Yes                     | Yes (24)                    | None              |
| 11       | 35, m          | Central left   | Adenoma         | No                          | Yes (98)                    | Bilateral adrenalectomy |
| 12       | 25, f          | Central right  | pos. Crooke hyaline | No                     | No (72)                     | Drug-treated       |
| 13       | 24, f          | Central right  | pos. Crooke hyaline | No                     | Yes (61)                    | Bilateral adrenalectomy |

Table 1 Baseline characteristics and remission rates following lateral one-third-gland resection

No., number; yrs, years; IPSS, inferior petrosal sinus sampling; m, male; f, female; ACTH, adrenocorticotropic hormone; pos., positive.

**Rates of remission**

At 3 months, remission was noted in three patients (23%) with histologically confirmed adenomas, in two patients (15%) with ACTH hyperplasia, and in one patient (8%) with positive Crooke’s hyaline degeneration (Fig. 2a). When dichotomizing patients into those with confirmed adenoma and those without, we noted early remission in three patients (60%) with histologically confirmed adenoma vs. three (38%) without (\(p = 0.59\)). Recurrence occurred in three patients (25%) with initial cortisol normalization. For the long-term control of hypercortisolism, bilateral adrenalectomy was required in four.
patients (33%), metyrapone therapy in three (25%), and pituitary radiosurgery in one patient (8%) (Table 1).

After a median (±SD) follow-up of 14±4 years, long-term remission was noted in 10 patients (77%): four (31%) with initially confirmed adenoma, three (23%) with ACTH-hyperplasia, two (15%) with positive Crooke-hyaline, and one patient (8%) with negative histology (Fig. 2b).

Complications of therapeutic interventions

No mortality due to the surgical intervention was noted. Postoperative complications consisted of rhinoliquorrhea in one patient—requiring temporary lumbar cerebrospinal fluid drain—and transient diabetes insipidus in another patient. New postoperative deficits requiring hormonal replacement were noted in two patients (15%), with testosterone replacement in one patient and additional growth hormone replacement in a patient with preoperative thyrotropic deficiency. We noted no vascular injuries, meningitis, or abscesses [57].

Discussion

Our data show that in CD patients with failed intraoperative adenoma visualization, (i) lateral one-third gland resection resulted in low rates of additional pituitary insufficiencies, but also in low cure rates of hypercortisolism, and (ii) high long-term remission rates (>10 years) can be attained, but only with an interdisciplinary multimodal approach.

CD is the most challenging disorder among hormone-secreting pituitary tumors [42, 54]. This has been attributed to difficulty both in the diagnosis and treatment of primarily microadenomas, along with the accuracy of tests in the assessment of endogenous hypercortisolism [7]. TSS is considered the first-line treatment for CD, providing remission in 59–90% of patients in dedicated tertiary pituitary centers [33]. Thereby, a risk factor for persistent hypercortisolism has been attributed to unsuccessful intraoperative adenoma identification [19, 33, 51]. For these cases, total hypophysectomy or hemi-hypophysectomy has been proposed—but at the expense of hypopituitarism [55]. Our approach resulted in low morbidity and long-term cure in 31% of patients. Likewise, early remission has been described in 11 CD patients (38%) with negative adenoma identification and subsequent hemihypophysectomy [35]. In the other 29 patients (62%) of their cohort, additional treatments such as adrenalectomy or radiotherapy were required. However, the authors reported no specific morbidity or rates of associated hypopituitarism [35]. Instead, in patients with two-thirds pituitary gland resection, favorable long-term remission rates were reported in 18 (82%) of the 22 patients and new endocrine deficits requiring hormone replacement in 9% [19]. While we likewise noted low rates of pituitary insufficiency, we could not attain remission rates as high as those reported by Carr et al. when we limited the resection to the lateral one-third of the pituitary gland [35]. This is of interest given that the rate of histologically confirmed adenomas reported by Carr and colleagues was lower than we noted in our series (27% vs. 38% in our cohort) [19]. This finding might underscore the hypothesis that unsuccessful histological adenoma confirmation does not seem to be the only predictor of a low remission rate. In fact, failure of histologic confirmation of an ACTH source is an intriguing finding, as remission rates are reported even in the absence of histological adenoma confirmation [67]. Nevertheless, most findings report on a lower initial remission rate and a higher long-term recurrence rate in patients without histological evidence of an adenoma [51]. On the other hand, the higher remission rates reported by Carr et al. might be due to removal of more pituitary tissue, thus increasing the likelihood of removing parts of the adenoma [39]. It is thus conceivable that removing adenohypophyseal corticotroph tissue in the central region of the gland known as the mucoid wedge might increase the chance for long-term cure [39]. Comtois and colleagues reported on 11 patients with absent intraoperative adenoma visualization, in whom a partial hypophysectomy of the central mucoid wedge was performed. This resulted in some remission but significantly lower cure rates as compared to those patients with intraoperative adenoma identification [25]. However, Carr and colleagues also reported that unlike Comtois’ observation [25], in their extensive experience with CD microadenomas, tumors were more commonly located in the lateral gland [19]. This underlines the finding that ACTH adenomas were localized in the lateral aspect of the pituitary gland in the majority of cases [37]. Likewise, bilateral IPS sampling in Cushing patients confirms a lateralization in the majority of cases [19, 37]. In the rare event of negative intraoperative adenoma visualization, the possibility of ectopic ACTH secretion has yet to be considered, despite high sensitivity and specificity attributed to bilateral IPSS [7, 10]. There have been several attempts to improve the predictive value of the intersinus ACTH gradient. In 2012, Mulligan and colleagues demonstrated improved adenoma lateralization using a prolactin-adjusted intersinus ACTH gradient of > 1.4 in their series [44]. Namely, IPSS prolactin can help to confirm correct catheter placement during venous sampling, thus improving differentiation between CD and EAS in the absence of proper IPS venous efflux [26, 50, 53]. However, further evaluation of the prolactin-adjusted ACTH ratio is needed to prove reliable surgical guidance [50]. Also, it has been suggested that anatomical variation like intersinus communication might explain sampling
failures [53]. In our previous work, we noted that IPS asymmetry did not diminish the prediction of the adenoma side [8]. However, the small sample size of this cohort precludes us from undertaking statistical analysis to compare outcome with regard to outflow symmetry. In addition, we have to keep in mind that surgeon experience is of particular importance to guarantee a favorable outcome in the treatment of CD [17, 36].

Given that CD is most commonly caused by a microadenoma, tissue for pathologic diagnosis using standard techniques might be very limited during surgical exploration [29]. While we sent suspicious tissue for frozen sectioning and proceeded with lateral one third hypophysectomy in the case of a negative result, it must be taken into consideration that the reliability of frozen results varies considerably. It has been shown that the addition of intraoperative cytological analyses during surgery provides a useful armamentarium in the diagnosis of CD [52]. In fact, in some cases, the presence of an adenoma can only be proven by cytological preparation, which improves the adenoma identification rate and surgical outcome compared to classical immunostaining methods [38].

Given the similar remission rates attained when limiting the approach to the lateral two-thirds compared to hemihypophysectomy or subtotal hypophysectomy, subtotal resection might be preferred with regard to postoperative pituitary hormone insufficiency, although results remain ambiguous [17, 19]. As for ACTH-producing adenomas, the risk of postoperative pituitary dysfunction can be higher than for other types of pituitary adenomas, given the need for more extensive intraoperative dissection of the pituitary gland, even in the case of small adenomas [56]. Subtotal hypophysectomy results in new hypopituitarism, with incidence rates ranging from 1 to 35% [23, 33, 35]. Interestingly, Rees and colleagues noted that the extent of surgical exploration predicted the development of hypopituitarism (88% total hypophysectomy, 33% hemi-hypophysectomy, 14% selective adenectomy), but not remission (75% total hypophysectomy, 87% hemihypophysectomy, 71% selective adenectomy) in CD patients [55]. More surprisingly, Yamada et al. reported that none of their 10 patients with hemi-hypophysectomy was not represented in the cohort presented here.

Subtotal hypophysectomy might be associated with higher gross total tumor removal [40], but results remain ambiguous [2]. In the treatment of CD, there seem to be no clear advantages of a purely endoscopic approach in terms of clinical outcome [1, 16, 45]. In particular, endoscopic surgery for patients with CD has been shown to have comparable results for microadenomas, with presumably better results for macroadenomas [14], which were not represented in the cohort presented here.

To sum up, limiting pituitary gland resection to the lateral one-third is a safe approach with favorable outcome in the face of new endocrine deficits, but remission rates are low.

Study limitations

The number of patients in our study is relatively small, and statistical uncertainty owing to this small sample size precluded us from undertaking statistical analysis to compare outcome within the subgroups (i.e., adenoma, ACTH hyperplasia, or positive Crooke-hyaline), or with regard to outflow symmetry encountered during IPS. However, it offers reliable insight derived from long-term data obtained over two decades with a follow-up of 14 years.

In contrast to microscopic TSS, an endoscopic approach might be associated with higher gross total tumor removal [40], but results remain ambiguous [2]. In the treatment of CD, there seem to be no clear advantages of a purely endoscopic approach in terms of clinical outcome [1, 16, 45]. In particular, endoscopic surgery for patients with CD has been shown to have comparable results for microadenomas, with presumably better results for macroadenomas [14], which were not represented in the cohort presented here.

Given the long-term follow-up with recruitment of patients starting as early as 1997, patients were screened with a 1.5 Tesla MRI for the depiction of a microadenoma [6]. While some authors support the use of contrast-enhanced 3 Tesla MRI for CD, most of these studies comparing the detection rate of the pituitary 3 Tesla and 1.5 Tesla MRI are using different imaging protocols, thus limiting the diagnostic accuracy of high-field-strength MRI in patients with CD [65]. In particular, a higher magnetic field might not be advantageous in the diagnosis of microadenomas per se [32, 65].
Conclusions

In CD patients with failed intraoperative adenoma visualization, lateral one-third gland resection resulted in low morbidity and long-term remission in 31% of patients without the need for additional therapies. Bearing in mind the sample size of this audit, the indication for lateral one-third-gland resection has to be critically appraised and discussed with the patients before surgery.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s00701-021-04830-2.

Acknowledgements The assistance of Ms. Jeannie Wurz in editing the manuscript is greatly appreciated. We express our gratitude to Professor Rolf W. Seiler (RWS), M.D., for granting access to his personal operative recordings. We thank Daniela Miescher for her drawing of the surgical approach used in this disease.

Funding Open access funding provided by Universität Bern.

Declarations

Competing interests The authors declare no competing interests.

Ethical standards and patient consent The Human Research Ethics Committee of Bern (Kantonale Ethikkommission KEK Bern, Bern, Switzerland) approved the project (KEK n° 10-10-2006 and 8-11-2006). The study was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Almutairi RD, Muskens IS, Cote DJ, Dijkstra MD, Kavouridis VK, Crocker E, Ghazawi K, Broekman MLD, Smith TR, Mekary RA, Zaidi HA (2018) Gross total resection of pituitary adenomas after endoscopic vs. microscopic transsphenoidal surgery: a meta-analysis. Acta Neurochir 160:1005–1021. https://doi.org/10.1007/s00701-017-3438-z
2. Ammirati M, Wei L, Ciric I (2013) Short-term outcome of endoscopic versus microscopic pituitary adenoma surgery: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 84:843–849. https://doi.org/10.1136/jnnp-2012-303194
3. Anderegg L, Frey J, Andres RH, El-Koussy M, Beck J, Seiler RW, Christ E (2017) 10-year follow-up study comparing primary medical vs. surgical therapy in women with prolactinomas. Endocrine 55:223–230. https://doi.org/10.1007/s12020-016-1115-2
4. Anderegg L, Frey J, Andres RH, El-Koussy M, Beck J, Seiler RW, Christ E (2017) Long-term follow-up of primary medical versus surgical treatment of prolactinomas in men: effects on hyperprolactinemia, hypogonadism, and bone health. World Neurosurg 97:595–602. https://doi.org/10.1016/j.wneu.2016.10.059
5. Anderegg L, Frey J, Andres RH, Luedi MM, Widmer HR, Beck J, Mariani L, Christ E (2021) Persistent bone impairment despite long-term control of hyperprolactinemia and hypogonadism in men and women with prolactinomas. Sci Rep 11:5122. https://doi.org/10.1038/s41598-021-84606-x
6. Anderegg L, Frey J, Christ E (2020) Long-term IGF-1 monitoring in prolactinoma patients treated with cabergoline might not be indicated. Endocrine. https://doi.org/10.1007/s12020-020-02557-1
7. Anderegg L, Gralla J, Schroth G, Mordasini P, Andres RH, Widmer HR, Luedi MM, Kellner F, Beck J, Mariani L, Ozdoba C, Christ E (2019) Influence of inferior petrosal sinus drainage symmetry on detection of adenomas in Cushing’s syndrome. J Neuroradiol. https://doi.org/10.1016/j.neurad.2019.05.004
8. Anderegg L, Gralla J, Schroth G, Mordasini P, Andres RH, Widmer HR, Luedi MM, Kellner F, Beck J, Mariani L, Ozdoba C, Christ E (2021) Influence of inferior petrosal sinus drainage symmetry on detection of adenomas in Cushing’s syndrome. J Neuroradiol 48:10–15. https://doi.org/10.1016/j.neurad.2019.05.004
9. Anderegg L, Mon M, Kellner-Weldon F, Christ E (2017) Cluster headache and macroadenoma: Case report of a rare, but potential important causality. J Clin Neurosci 40:62–64. https://doi.org/10.1016/j.jocn.2017.01.028
10. Anderegg L, Schroth G, Gralla J, Seiler R, Mariani L, Beck J, Widmer HR, Andres RH, Christ E, Ozdoba C (2012) Selective inferior petrosal sinus sampling without venous outflow diversion in the detection of a pituitary adenoma in Cushing’s syndrome. Neuroradiology 54:495–503. https://doi.org/10.1007/s00234-011-0915-6
11. Aranda G, Ensenat J, Mora M, Puig-Domingo M, Martinez de Osaba M, Casals G, Verger E, Ribalta MT, Hanzu FA, Halperin I (2015) Long-term remission and recurrence rate in a cohort of Cushing’s disease: the need for long-term follow-up. Pituitary 18:142–149. https://doi.org/10.1007/s11102-014-0567-8
12. Bendiford G, Campi A (2002) Aberrant inferior petrosal sinus: unusual transvenous approach to the cavernous sinus. Neuroradiology 44:158–163
13. Braun LT, Rubinstein G, Zopp S, Vogel F, Schmid-Tannwald C, Escudero MP, Honegger J, Ladurner R, Reincke M (2020) Recurrence after pituitary surgery in adult Cushing’s disease: a systematic review on diagnosis and treatment. Endocrine 70:218–231. https://doi.org/10.1007/s12020-020-02432-z
14. Broersen LHA, Biermasz NR, van Furth WR, de Vries F, Verstegen MJT, Dekkers OM, Pereira AM (2018) Endoscopic vs. microscopic transsphenoidal surgery for Cushing’s disease: a systematic review and meta-analysis. Pituitary 21:524–534. https://doi.org/10.1007/s11102-018-0893-3
15. Broersen LHA, Jha M, Biermasz NR, Pereira AM, Dekkers OM (2018) Effectiveness of medical treatment for Cushing’s syndrome: a systematic review and meta-analysis. Pituitary 21:631–641. https://doi.org/10.1007/s11102-018-0897-z
16. Broersen LHA, van Haalen FM, Biermasz NR, Lobatto DJ, Verstegen MJT, van Furth WR, Dekkers OM, Pereira AM (2019) Microscopic versus endoscopic transsphenoidal surgery in the Leiden cohort treated for Cushing’s disease: surgical outcome, mortality, and complications. Orphanet J Rare Dis 14:64. https://doi.org/10.1186/s13023-019-1038-0
17. Bunevicius A, Laws ER, Vance ML, Iuliano S, Sheehan J (2019) Surgical and radiosurgical treatment strategies for Cushing’s disease. J Neuro-Onccol 145:403–413. https://doi.org/10.1007/s11060-019-03325-6

18. Burke WT, Penn DL, Repetti CS, Iuliano S, Laws ER (2019) Outcomes after repeat transsphenoidal surgery for recurrent cushing disease: updated. Neurosurgery. https://doi.org/10.1093/neuros/nyz193

19. Carr SB, Kleinschmidt-DeMasters BK, Kerr JM, Kiseljak-Vassilides K, Wierman ME, Lillehei KO (2018) Negative surgical exploration in patients with Cushing’s disease: benefit of two-thirds gland resection on remission rate and a review of the literature. J Neurosurg 129:1260–1267. https://doi.org/10.1093/jns/jny290

20. Cebula H, Baussart B, Villa C, Assie G, Boulin A, Foubert L, Aldea S, Bennis S, Bernier M, Proust F, Gaillard S (2017) Efficacy of endoscopic transsphenoidal surgery for Cushing’s disease in 230 patients with positive and negative MRI. Acta Neurochir 159:1227–1236. https://doi.org/10.1007/s00701-017-3140-1

21. Chiloiro S, Giampietro A, Raffaelli M, D’Amato G, Bima C, Lauretti L, Anile C, Lombardi CP, Rindi G, Bellantone R, De Marinis L, Pontecorvi A, Bianchi A (2019) Synchronous bilateral adrenalectomy in ACTH-dependent hypercortisolism: predictors, biomarkers and outcomes. Endocrine 66:642–649. https://doi.org/10.1007/s12020-019-02091-9

22. Chitithoina P, Talagala SL, Merkle H, Sarlis JE, Montgomery BK, Piazza MG, Scott G, Ray-Chaudhury A, Lonser RR, Oldfield EH, Koretsky AP, Butman JA (2016) Endosphenoidal coil for intraoperative magnetic resonance imaging of the pituitary gland during transsphenoidal surgery. J Neurosurg 125:1451–1460. https://doi.org/10.3171/2015.11.JNS151465

23. Ciric I, Ragan A, Baumgartner C, Pierce D (1997) Complications of transsphenoidal surgery: results of a national survey, review of the literature, and personal experience. Neurosurgery 40:225–236; discussion 236–227. https://doi.org/10.1093/neuros/40.2.225

24. Cohen-Cohen S, Gardner PA, Alves-Belo JT, Truong HQ, Snyderman CH, Wang EW, Fernandez-Miranda JC (2018) The medial wall of the cavernous sinus. Part 2: Selective medial wall resection in 50 pituitary adenoma patients. J Neurosurg 131:131–140. https://doi.org/10.1093/jns/jny185

25. Comtois R, Beauregard H, Hardy J, Robert F, Sonna M (1993) High prolactin levels in patients with Cushing’s disease without pathological evidence of pituitary adenoma. Clin Endocrinol 38:515–520. https://doi.org/10.1111/j.1365-2265.1993.tb02141.x

26. De Sousa SMC, McCormack AL, McGrath S, Torpy DJ (2017) Prolactin correction for adequacy of petrosal sinus cannulation may diminish diagnostic accuracy in Cushing’s disease. Clin Endocrinol 87:515–522. https://doi.org/10.1111/cen.13401

27. Dichek HL, Nieman NL, Oldfield EH, Pass HI, Malley JD, Cutler GB Jr (1994) A comparison of the standard high dose dexamethasone suppression test and the overnight 8-mg dexamethasone suppression test for the differential diagnosis of adrenocorticotropin-dependent Cushing’s syndrome. J Clin Endocrinol Metab 78:418–422. https://doi.org/10.1210/jcem.78.2.806630

28. Donofrio A, Losa M, Gemma M, Giudice L, Barzaghi LR, Mortini P (2017) Safety of transsphenoidal microsurgical approach in patients with an ACTH-secreting pituitary adenoma. Endocrine 58:303–311. https://doi.org/10.1007/s12020-016-1214-0

29. Erfe JM, Perry A, McClaskey J, Inzucchi SE, James WS, Eid T, Bronen RA, Mahajan A, Huttner A, Santos F, Spencer D (2018) Long-term outcomes of tissue-based ACTH-antibody assay-guided transsphenoidal resection of pituitary adenomas in Cushing disease. J Neurosurg 129:629–641. https://doi.org/10.3171/2017.3. JNS162245

30. Fernandez-Miranda JC, Gardner PA, Rastelli MM Jr, Peris-Celda M, Koutouroussi M, Peace D, Snyderman CH, Rhoton AL Jr (2014) Endoscopic transsphenoidal surgery: results of a national survey, review of the literature, and personal experience. Neurosurgery. https://doi.org/10.1093/neuros/nyz193

31. Fernandez-Miranda JC, Zwegarman NT, Abhinav K, Lieber S, Wang EW, Snyderman CH, Gardner PA (2018) Cavernous sinus compartments from the endoscopic transsphenoidal approach: anatomical considerations and surgical relevance to adenoma surgery. J Neurosurg 129:430–441. https://doi.org/10.3171/2017.2. JNS162214

32. Fukuhara N, Inoshita N, Yamaguchi-Okada M, Tatsushima K, Takeshita A, Ito J, Takeuchi Y, Yamada S, Nishikawa H (2019) Outcomes of three-Tesla magnetic resonance imaging for the identification of pituitary adenoma in patients with Cushing’s disease. Endoc J 66:259–264. https://doi.org/10.1507/endocr.JE18-0458

33. Hammer GD, Tyrell JB, Lamborn KR, Applebury CB, Hannegan ET, Bell S, Rahl R, Lu A, Wilson CB (2004) Transphenoidal microsurgery for Cushing’s disease: initial outcome and long-term results. J Clin Endocrinol Metab 89:6348–6357. https://doi.org/10.1210/jc.2003-032180

34. Hirsch D, Shimon I, Manistersky Y, Aviran-Barak N, Amtai O, Nadler V, Alboim S, Kopel V, Tsvetov (2018) Cushing’s syndrome: comparison between Cushing’s disease and adenocortical Cushing’s. Endocr 62:712–720. https://doi.org/10.1007/s12020-018-1709-y

35. Hofmann BM, Bluva M, Martinez R, Buchfelder M, Muller OA, Fahrbusch R (2008) Long-term results after microsurgery for Cushing disease: experience with 426 primary operations over 35 years. J Neurosurg 108:9–18. https://doi.org/10.3171/2008.10.010009

36. Honegger J, Grimm F (2018) The experience with transsphenoidal surgery and its importance to outcomes. Pituitary 21:545–555. https://doi.org/10.1007/s11120-018-0904-4

37. Invitti C, Pecori Giraldi F, de Martin M, Cavagnini F (1999) Diagnosis and management of Cushing’s syndrome: results of an Italian multicentre study. Study Group of the Italian Society of Endocrinology on the Pathophysiology of the Hypothalamic-Pituitary-Adrenal Axis. J Clin Endocrinol Metab 84:440–448. https://doi.org/10.1210/jcem.84.2.5465

38. Kurosaki M, Luedecke DK, Knappe UJ, Flitsch J, Saeger W (2000) The value of intraoperative cytology during transsphenoidal surgery for ACTH-secreting microadenoma. Acta Neurochir 142:865–870. https://doi.org/10.1007/s007010007091

39. La Rosa S, Uccella S, Maines L, Marchet S, Placidi C, Vigetti D, Capella C (2008) Characterization of e-kit (CD117) expression in human normal pituitary cells and pituitary adenomas. Endocr Pathol 19:104–111. https://doi.org/10.1007/s12022-008-9032-4

40. Li A, Liu W, Cao P, Zheng Y, Bu Z, Zhou T (2017) Endoscopic versus microscopic transsphenoidal surgery in the treatment of pituitary adenoma: a systematic review and meta-analysis. World Neurosurg 101:236–246. https://doi.org/10.1016/j.wneu.2017.01.022

41. Mayberg M, Reintjes S, Patel A, Moloney K, Mercado J, Carlson A, Scanlan J, Broyles F (2018) Dynamics of postoperative serum cortisol after transsphenoidal surgery for Cushing’s disease: implications for immediate reoperation and remission. J Neurosurg 129:1268–1277. https://doi.org/10.3171/2017.6.JNS17635

42. Moltich ME (2017) Diagnosis and treatment of pituitary adenomas: a review. JAMA 317:516–524. https://doi.org/10.1001/jama.2016.19699

43. Morelli V, Minelli L, Eller-Vainicher C, Palmieri S, Cairoli E, Spada A, Arosio M, Chiodini I (2018) Predictability of hypoa adrenalism occurrence and duration after adrenalectomy for ACTH-independent hypercortisolism. J Endocrinol Invest 41:485–493. https://doi.org/10.4068/jsei17-0788-6
